-

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Award marks company’s 11th consecutive year of receiving this honor

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle. The award marks the 11th consecutive year that Veracyte has received this honor.

The Bay Area Top Workplace award winners are determined based solely on employee feedback gathered by Energage, an employee engagement technology partner. The firm administers a confidential survey that measures employee experience and its component themes, including the degree to which employees feel respected and supported, enabled to grow and empowered to execute, among others.

“We are deeply honored to be recognized as a Top Workplace, which underscores our commitment to our employees and to our vision of transforming cancer care for patients all over the world,” said Marc Stapley, Veracyte’s chief executive officer. “At Veracyte we believe that our employees are our greatest asset and that each plays a key role in our work to guide clinicians to the right next steps for their patients, while we collectively focus on building what’s next in cancer care.”

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
media@veracyte.com
650-380-4413

Veracyte, Inc.

NASDAQ:VCYT

Release Summary
Veracyte is Named a Greater Bay Area Top Workplace by the San Francisco Chronicle.
Release Versions
$Cashtags

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
media@veracyte.com
650-380-4413

Social Media Profiles
More News From Veracyte, Inc.

Veracyte Announces First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte’s CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approac...

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers...

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will be av...
Back to Newsroom